Business Wire·Nov 12, 2026, 7:38 PM ET

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology priced an underwritten public offering of 15,000,000 common shares at $10.00 per share.
The offering is expected to generate gross proceeds of $150 million before deducting underwriting discounts, commissions, & offering expenses.
Underwriters have a 30-day option to purchase up to an additional 2,250,000 shares at the public offering price.
All shares are being sold by Vir Biotechnology, with closing expected on November 16, 2026.
Leerink Partners, Morgan Stanley, & Evercore ISI are acting as bookrunning managers, while Raymond James serves as co-manager.
The offering is pursuant to a registration statement filed with the SEC on November 12, 2026, which became effective upon filing.
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases & cancer, including programs for chronic hepatitis delta & PRO-XTEN dual-masked T-cell engagers.